Advertisement

Psychopharmacology

, Volume 235, Issue 7, pp 2113–2121 | Cite as

Cognitive profile of ketamine-dependent patients compared with methamphetamine-dependent patients and healthy controls

  • Liang-Jen Wang
  • Chih-Ken Chen
  • Shih-Ku Lin
  • Yi-Chih Chen
  • Ke Xu
  • Ming-Chyi HuangEmail author
Original Investigation

Abstract

Background

Ketamine has emerged as a major substance of abuse worldwide and has been listed with methamphetamine (METH) as two of the most widely available illicit substances in Taiwan. Only a few studies have examined the long-term consequences of chronic and heavy ketamine abuse. We compared the cognitive function of ketamine-dependent patients with that of METH-dependent patients and healthy controls.

Methods

We recruited 165 participants (58 ketamine-dependent and 49 METH-dependent patients who sought treatment and 58 healthy controls) and evaluated them by using a cognitive test battery, the Brief Assessment of Cognition in Schizophrenia, with scores being estimated in reference to normative data in general population.

Results

The ketamine-dependent patients had significantly poorer performance than did the controls in many cognitive tests, including verbal memory, motor speed, verbal fluency, and attention and processing speed, and the battery as a whole. METH-dependent patients exhibited poorer function in motor speed, verbal fluency, and attention and processing speed. The ketamine group performed poorer than did METH group in the domains of verbal memory, working memory, and attention and processing speed and the composite battery scores. A previous experience of ketamine-induced psychotomimetic symptoms, using higher doses of ketamine, and longer abstinence appeared to be associated with performance in some tests; however, the significance disappeared after multiple comparison correction.

Conclusions

The ketamine-dependent patients had impaired cognitive function, and METH-dependent patients exhibited intermediate performance between ketamine-dependent patients and healthy controls. Given the growing population of ketamine abusers, public education on the cognitive consequences should be provided.

Keywords

Ketamine Methamphetamine Substance dependence Cognition Psychosis 

Notes

Funding sources

This study was supported by grants from Ministry of Science and Technology, Taiwan (98-2314-B-182-001-MY3, 101-2314-B-182-080, 102-2314-B-182-007, 103-2628-B-532-001-MY3, and 106-2314-B-532-005-MY3), Chang Gung Memorial Hospital, Taiwan (CMRPG2D0261, CMRPG8C1291, and CMRPG8D0481), and Taipei City Hospital, Taiwan (10601-62-018 and 10701-62-029).

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

References

  1. Bokor G, Anderson PD (2014) Ketamine: an update on its abuse. J Pharm Pract 27(6):582–586CrossRefPubMedGoogle Scholar
  2. Chan KW, Lee TM, Siu AM, Wong DP, Kam CM, Tsang SK, Chan CC (2013) Effects of chronic ketamine use on frontal and medial temporal cognition. Addict Behav 38:2128–2132CrossRefPubMedGoogle Scholar
  3. Chen WJ, Liu SK, Chang CJ, Lien YJ, Chang YH, Hwu HG (1998) Sustained attention deficit and schizotypal personality features in nonpsychotic relatives of schizophrenic patients. Am J Psychiatr 155:1214–1220CrossRefPubMedGoogle Scholar
  4. Chen WJ, Fu TC, Ting TT, Huang WL, Tang GM, Hsiao CK, Chen CY (2009) Use of ecstasy and other psychoactive substances among school-attending adolescents in Taiwan: national surveys 2004-2006. BMC Public Health 9:27CrossRefPubMedPubMedCentralGoogle Scholar
  5. Chen CK, Lin SK, Chen YC, Huang MC, Chen TT, Ree SC, Wang LJ (2015a) Persistence of psychotic symptoms as an indicator of cognitive impairment in methamphetamine users. Drug Alcohol Depend 148:158–164CrossRefPubMedGoogle Scholar
  6. Chen YC, Wang LJ, Lin SK, Chen CK (2015b) Neurocognitive profiles of methamphetamine users: comparison of those with or without concomitant ketamine use. Subst Use Misuse 50:1778–1785CrossRefPubMedGoogle Scholar
  7. Chevallier C, Batisse A, Batel P, Benso V, Segouin C, Marillier M, Djezzar S (2015) Ketamine: medical indications, recreational use and abuse liability. Euro Psychiatry 30:478CrossRefGoogle Scholar
  8. Critchlow DG (2006) A case of ketamine dependence with discontinuation symptoms. Addiction 101:1212–1213CrossRefPubMedGoogle Scholar
  9. Cruickshank CC, Dyer KR (2009) A review of the clinical pharmacology of methamphetamine. Addiction 104:1085–1099CrossRefPubMedGoogle Scholar
  10. Dean AC, Groman SM, Morales AM, London ED (2013) An evaluation of the evidence that methamphetamine abuse causes cognitive decline in humans. Neuropsychopharmacol: Off Publ Am Coll Neuropsychopharmacol 38:259–274CrossRefGoogle Scholar
  11. Dillon P, Copeland J, Jansen K (2003) Patterns of use and harms associated with non-medical ketamine use. Drug Alcohol Depend 69:23–28CrossRefPubMedGoogle Scholar
  12. Domier CP, Monterosso JR, Brody AL, Simon SL, Mendrek A, Olmstead R, Jarvik ME, Cohen MS, London ED (2007) Effects of cigarette smoking and abstinence on Stroop task performance. Psychopharmacology 195:1–9CrossRefPubMedPubMedCentralGoogle Scholar
  13. Domino EF (2010) Taming the ketamine tiger. 1965. Anesthesiology 113:678–684PubMedGoogle Scholar
  14. Durieux ME (1995) Inhibition by ketamine of muscarinic acetylcholine receptor function. Anesth Analg 81:57–62PubMedGoogle Scholar
  15. Feng LY, Yu WJ, Chang WT, Han E, Chung H, Li JH (2016) Comparison of illegal drug use pattern in Taiwan and Korea from 2006 to 2014. Subst Abuse Treat Preven Pol 11:34CrossRefGoogle Scholar
  16. Glasner-Edwards S, Mooney LJ (2014) Methamphetamine psychosis: epidemiology and management. CNS Drugs 28:1115–1126CrossRefPubMedPubMedCentralGoogle Scholar
  17. Gozzi A, Turrini G, Piccoli L, Massagrande M, Amantini D, Antolini M, Martinelli P, Cesari N, Montanari D, Tessari M, Corsi M, Bifone A (2011) Functional magnetic resonance imaging reveals different neural substrates for the effects of orexin-1 and orexin-2 receptor antagonists. PLoS One 6:e16406CrossRefPubMedPubMedCentralGoogle Scholar
  18. Hanna RC, Shalvoy A, Cullum CM, Ivleva EI, Keshavan M, Pearlson G, Hill SK, Sweeney JA, Tamminga CA, Ghose S (2016) Cognitive function in individuals with psychosis: moderation by adolescent cannabis use. Schizophr Bull 42:1496–1503CrossRefPubMedPubMedCentralGoogle Scholar
  19. Hart CL, Marvin CB, Silver R, Smith EE (2012) Is cognitive functioning impaired in methamphetamine users? A critical review. Neuropsychopharmacol: Off Publ Am Coll Neuropsychopharmacol 37:586–608CrossRefGoogle Scholar
  20. Hochberger WC, Hill SK, Nelson CL, Reilly JL, Keefe RS, Pearlson GD, Keshavan MS, Tamminga CA, Clementz BA, Sweeney JA (2016) Unitary construct of generalized cognitive ability underlying BACS performance across psychotic disorders and in their first-degree relatives. Schizophr Res 170:156–161CrossRefPubMedGoogle Scholar
  21. Huang MC, Yang SY, Lin SK, Chen KY, Chen YY, Kuo CJ, Hung YN (2016) Risk of cardiovascular diseases and stroke events in methamphetamine users: a 10-year follow-up study. J Clin Psychiatry 77:1396–1403CrossRefPubMedGoogle Scholar
  22. Iudicello JE, Woods SP, Vigil O, Scott JC, Cherner M, Heaton RK, Atkinson JH, Grant I, Group HIVNRC (2010) Longer term improvement in neurocognitive functioning and affective distress among methamphetamine users who achieve stable abstinence. J Clin Exp Neuropsychol 32:704–718CrossRefPubMedPubMedCentralGoogle Scholar
  23. Jevtovic-Todorovic V, Wozniak DF, Benshoff ND, Olney JW (2001) A comparative evaluation of the neurotoxic properties of ketamine and nitrous oxide. Brain Res 895:264–267CrossRefPubMedGoogle Scholar
  24. Joe Laidler KA (2005) The rise of club drugs in a heroin society: the case of Hong Kong. Subst Use Misuse 40:1257–1278CrossRefPubMedGoogle Scholar
  25. Johanson CE, Frey KA, Lundahl LH, Keenan P, Lockhart N, Roll J, Galloway GP, Koeppe RA, Kilbourn MR, Robbins T, Schuster CR (2006) Cognitive function and nigrostriatal markers in abstinent methamphetamine abusers. Psychopharmacology 185:327–338CrossRefPubMedGoogle Scholar
  26. Kalechstein AD, Newton TF, Green M (2003) Methamphetamine dependence is associated with neurocognitive impairment in the initial phases of abstinence. J Neuropsychiatry Clin Neurosci 15:215–220CrossRefPubMedGoogle Scholar
  27. Kalsi SS, Wood DM, Dargan PI (2011) The epidemiology and patterns of acute and chronic toxicity associated with recreational ketamine use. Emerging Health Threats J 4:7107CrossRefGoogle Scholar
  28. Kapur S, Seeman P (2002) NMDA receptor antagonists ketamine and PCP have direct effects on the dopamine D(2) and serotonin 5-HT(2)receptors-implications for models of schizophrenia. Mol Psychiatry 7:837–844CrossRefPubMedGoogle Scholar
  29. Keefe RS, Goldberg TE, Harvey PD, Gold JM, Poe MP, Coughenour L (2004) The Brief Assessment of Cognition in Schizophrenia: reliability, sensitivity, and comparison with a standard neurocognitive battery. Schizophr Res 68:283–297CrossRefPubMedGoogle Scholar
  30. Keefe RS, Poe M, Walker TM, Kang JW, Harvey PD (2006) The Schizophrenia Cognition Rating Scale: an interview-based assessment and its relationship to cognition, real-world functioning, and functional capacity. Am J Psychiatry 163:426–432CrossRefPubMedGoogle Scholar
  31. Keefe RS, Harvey PD, Goldberg TE, Gold JM, Walker TM, Kennel C, Hawkins K (2008) Norms and standardization of the Brief Assessment of Cognition in Schizophrenia (BACS). Schizophr Res 102:108–115CrossRefPubMedGoogle Scholar
  32. Liao Y, Tang J, Corlett PR, Wang X, Yang M, Chen H, Liu T, Chen X, Hao W, Fletcher PC (2011) Reduced dorsal prefrontal gray matter after chronic ketamine use. Biol Psychiatry 69:42–48CrossRefPubMedGoogle Scholar
  33. London ED (2016) Impulsivity, stimulant abuse, and dopamine receptor signaling. Adv Pharmacol 76:67–84CrossRefPubMedGoogle Scholar
  34. London ED, Kohno M, Morales AM, Ballard ME (2015) Chronic methamphetamine abuse and corticostriatal deficits revealed by neuroimaging. Brain Res 1628:174–185CrossRefPubMedGoogle Scholar
  35. Mendrek A, Monterosso J, Simon SL, Jarvik M, Brody A, Olmstead R, Domier CP, Cohen MS, Ernst M, London ED (2006) Working memory in cigarette smokers: comparison to non-smokers and effects of abstinence. Addict Behav 31:833–844CrossRefPubMedGoogle Scholar
  36. Moghaddam B, Krystal JH (2012) Capturing the angel in “angel dust”: twenty years of translational neuroscience studies of NMDA receptor antagonists in animals and humans. Schizophr Bull 38:942–949CrossRefPubMedPubMedCentralGoogle Scholar
  37. Morgan CJ, Monaghan L, Curran HV (2004a) Beyond the K-hole: a 3-year longitudinal investigation of the cognitive and subjective effects of ketamine in recreational users who have substantially reduced their use of the drug. Addiction 99:1450–1461CrossRefPubMedGoogle Scholar
  38. Morgan CJ, Riccelli M, Maitland CH, Curran HV (2004b) Long-term effects of ketamine: evidence for a persisting impairment of source memory in recreational users. Drug Alcohol Depend 75:301–308CrossRefPubMedGoogle Scholar
  39. Morgan CJ, Muetzelfeldt L, Curran HV (2009) Ketamine use, cognition and psychological wellbeing: a comparison of frequent, infrequent and ex-users with polydrug and non-using controls. Addiction 104:77–87CrossRefPubMedGoogle Scholar
  40. Morgan CJ, Muetzelfeldt L, Curran HV (2010) Consequences of chronic ketamine self-administration upon neurocognitive function and psychological wellbeing: a 1-year longitudinal study. Addiction 105:121–133CrossRefPubMedGoogle Scholar
  41. Morgan CJ, Curran HV, Independent Scientific Committee on D (2012) Ketamine use: a review. Addiction 107:27–38CrossRefPubMedGoogle Scholar
  42. Okita K, Ghahremani DG, Payer DE, Robertson CL, Dean AC, Mandelkern MA, London ED (2016) Emotion dysregulation and amygdala dopamine D2-type receptor availability in methamphetamine users. Drug Alcohol Depend 161:163–170CrossRefPubMedPubMedCentralGoogle Scholar
  43. Okita K, Morales AM, Dean AC, Johnson MC, Lu V, Farahi J, Mandelkern MA, London ED (2017) Striatal dopamine D1-type receptor availability: no difference from control but association with cortical thickness in methamphetamine users. Mol PsychiatryGoogle Scholar
  44. Panenka WJ, Procyshyn RM, Lecomte T, MacEwan GW, Flynn SW, Honer WG, Barr AM (2013) Methamphetamine use: a comprehensive review of molecular, preclinical and clinical findings. Drug Alcohol Depend 129:167–179CrossRefPubMedGoogle Scholar
  45. Rabiner EA (2007) Imaging of striatal dopamine release elicited with NMDA antagonists: is there anything there to be seen? J Psychopharmacol 21:253–258CrossRefPubMedGoogle Scholar
  46. Scott JC, Woods SP, Matt GE, Meyer RA, Heaton RK, Atkinson JH, Grant I (2007) Neurocognitive effects of methamphetamine: A critical review and meta-analysis. Neuropsychol Rev 17(3):275–297CrossRefPubMedGoogle Scholar
  47. Simon SL, Domier C, Carnell J, Brethen P, Rawson R, Ling W (2000) Cognitive impairment in individuals currently using methamphetamine. Am J Add Am Acad Psych Alcoholism Addict 9:222–231Google Scholar
  48. Simon SL, Dean AC, Cordova X, Monterosso JR, London ED (2010) Methamphetamine dependence and neuropsychological functioning: evaluating change during early abstinence. J Stud Alcohol Drugs 71:335–344CrossRefPubMedPubMedCentralGoogle Scholar
  49. Sun L, Li Q, Li Q, Zhang Y, Liu D, Jiang H, Pan F, Yew DT (2014) Chronic ketamine exposure induces permanent impairment of brain functions in adolescent cynomolgus monkeys. Addict Biol 19:185–194CrossRefPubMedGoogle Scholar
  50. Tang WK, Liang HJ, Lau CG, Tang A, Ungvari GS (2013) Relationship between cognitive impairment and depressive symptoms in current ketamine users. J Stud Alcohol Drugs 74:460–468CrossRefPubMedGoogle Scholar
  51. Wang M, Wong AH, Liu F (2012) Interactions between NMDA and dopamine receptors: a potential therapeutic target. Brain Res 1476:154–163CrossRefPubMedGoogle Scholar
  52. Wang C, Zheng D, Xu J, Lam W, Yew DT (2013) Brain damages in ketamine addicts as revealed by magnetic resonance imaging. Front Neuroanat 7:23CrossRefPubMedPubMedCentralGoogle Scholar
  53. Wang LJ, Lin PY, Lee Y, Huang YC, Hsu ST, Hung CF, Chen CK, Chen YC, Wang YL, Tsai MC (2016) Validation of the Chinese version of Brief Assessment of Cognition in Schizophrenia. Neuropsychiatr Dis Treat 12:2819–2826CrossRefPubMedPubMedCentralGoogle Scholar
  54. Wang L-J, Huang Y-C, Hung C-F, Chen C-K, Chen Y-C, Lee P-Y, Wang S-M, Liu M-H, Lin C-J, Hsu S-T (2017) The chinese version of the brief assessment of cognition in schizophrenia: Data of a large-scale mandarin-speaking population. Arch Clin Neuropsychol 32(3):289–296CrossRefPubMedGoogle Scholar
  55. Yamamuro K, Makinodan M, Kimoto S, Kishimoto N, Morimoto T, Toritsuka M, Matsuoka K, Takebayashi Y, Takata T, Takahashi M, Tanimura Y, Nishihata Y, Matsuda Y, Ota T, Yoshino H, Iida J, Kishimoto T (2015) Differential patterns of blood oxygenation in the prefrontal cortex between patients with methamphetamine-induced psychosis and schizophrenia. Sci Rep 5:12107CrossRefPubMedPubMedCentralGoogle Scholar
  56. Yu H, Li Q, Wang D, Shi L, Lu G, Sun L, Wang L, Zhu W, Mak YT, Wong N, Wang Y, Pan F, Yew DT (2012) Mapping the central effects of chronic ketamine administration in an adolescent primate model by functional magnetic resonance imaging (fMRI). Neurotoxicology 33:70–77CrossRefPubMedGoogle Scholar
  57. Zhong N, Jiang H, Du J, Zhao Y, Sun H, Xu D, Li C, Zhuang W, Li X, Hashimoto K, Zhao M (2016) The cognitive impairments and psychological wellbeing of methamphetamine dependent patients compared with health controls. Prog Neuro-Psychopharmacol Biol Psychiatry 69:31–37CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of Child and Adolescent PsychiatryKaohsiung Chang Gung Memorial Hospital and Chang Gung University College of MedicineKaohsiungTaiwan
  2. 2.Department of Psychiatry, Chang Gung Memorial HospitalKeelungTaiwan
  3. 3.Chang Gung University School of MedicineTaoyuanTaiwan
  4. 4.Taipei City Psychiatric Center, Taipei City HospitalTaipeiTaiwan
  5. 5.Department of Psychiatry, School of Medicine, College of MedicineTaipei Medical UniversityTaipeiTaiwan
  6. 6.Department of Psychiatry, Yale School of MedicineNew HeavenUSA

Personalised recommendations